MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Levodopa-induced dyskinesias in Parkinson disease: A population-based cohort study in Olmsted County, MN (1991-2010)

P. Turcano, M. Mielke, C. Stang, J. Bower, J. Parisi, J. Cutsforth Gregory, E. Ahlskog, R. Savica (Rochester, MN, USA)

Meeting: 2018 International Congress

Abstract Number: 799

Keywords: Dyskinesias, Levodopa(L-dopa)

Session Information

Date: Sunday, October 7, 2018

Session Title: Epidemiology

Session Time: 1:45pm-3:15pm

Location: Hall 3FG

Objective: To assess the frequency of dyskinesias in a population based-cohort of Parkinson’s disease patients.

Background: Levodopa-induced dyskinesias are complications that may impact quality of life.

Methods: We utilized the 1991-2010 population-based, parkinsonism incident-cohort of Olmsted County, MN (N=669), accessed via the Rochester Epidemiology Project. From that parkinsonism cohort, we identified patients with Parkinson’s disease (PD) and abstracted information relating to levodopa-related dyskinesias.

Results: Of the 309 PD cases (46.2% of parkinsonisms), 279 (90.3%) were treated with levodopa. The vast majority (230/279; 82.4%) had been treated by a Mayo neurologist. Median age of levodopa initiation in this incidence cohort was 75 (range: 37-98 years) and duration of levodopa treatment was 6 years (range, 2 months to 19.8 years). Dyskinesias were documented in 30.1% (N=84). Among those with dyskinesias median time from levodopa-initiation to dyskinesias was 4 years (range: 2 months-20 years); 65.5% (55/84) developed dyskinesias within 5 years of levodopa initiation (9 within the first year of treatment). Dyskinesias were rated as mild in 57/84 (67.9%), moderate in 16/84 (19.1%) and severe in 9/84 (10.7%); dyskinesia severity was not reported in 2 cases. Dyskinesia severity led to levodopa adjustments (or amantadine) in 60.7% (51/84 of those with dyskinesias), with marked improvement in 23 (45.1%). All 13 dyskinetic patients that underwent deep brain stimulation (DBS) reported marked dyskinesia improvement. Post-mortem examination confirmed Lewy-body disease in all seven autopsied cases.

Conclusions: Levodopa-induced dyskinesias affected 30% of PD patients in our incident cohort. Mayo neurologists who favored optimized levodopa dosage treated most of the patients. Dyskinesias were severe in only 3% of all levodopa-treated PD patients (11% of all dyskinetic patients) with marked improvement among those treated with DBS.

To cite this abstract in AMA style:

P. Turcano, M. Mielke, C. Stang, J. Bower, J. Parisi, J. Cutsforth Gregory, E. Ahlskog, R. Savica. Levodopa-induced dyskinesias in Parkinson disease: A population-based cohort study in Olmsted County, MN (1991-2010) [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/levodopa-induced-dyskinesias-in-parkinson-disease-a-population-based-cohort-study-in-olmsted-county-mn-1991-2010/. Accessed May 17, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/levodopa-induced-dyskinesias-in-parkinson-disease-a-population-based-cohort-study-in-olmsted-county-mn-1991-2010/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Survey-Based study of marijuana used in Parkinson’s Disease patients
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley